StartTTNP • NASDAQ
add
Titan Pharmaceuticals, Inc. common stock
Seneste lukkekurs
4,80 $
Dagsinterval
4,53 $ - 4,81 $
Årsinterval
4,24 $ - 14,80 $
Markedsværdi
4,27 mio. USD
Gns. volumen
19,75 t
P/E-værdi
-
Udbytteprocent
-
Primær børs
NASDAQ
Markedsnyheder
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
| (USD) | jun. 2024info | År til år-ændring |
|---|---|---|
Indtægt | — | — |
Driftsudgifter | 2,07 mio. | 68,76 % |
Nettoindtægt | -2,09 mio. | -31,97 % |
Overskudsgrad | — | — |
Earnings per share | — | — |
EBITDA | -2,07 mio. | -33,70 % |
Effektiv afgiftssats | — | — |
Årsbalance
Samlede aktiver
Samlede passiver
| (USD) | jun. 2024info | År til år-ændring |
|---|---|---|
Kontanter og korttidsinvesteringer | 4,09 mio. | 3.797,14 % |
Samlede aktiver | 4,35 mio. | 435,71 % |
Samlede passiver | 356,00 t | -80,72 % |
Samlet egenkapital | 3,99 mio. | — |
Shares outstanding | 914,23 t | — |
Kurs/indre værdi | 1,10 | — |
Afkast af aktiver | -94,31 % | — |
Afkast af kapital | -102,53 % | — |
Pengestrøm
Nettoændring i likviditet
| (USD) | jun. 2024info | År til år-ændring |
|---|---|---|
Nettoindtægt | -2,09 mio. | -31,97 % |
Pengestrøm fra drift | -2,07 mio. | -85,97 % |
Pengestrøm fra investering | — | — |
Pengestrøm fra finansiering | — | — |
Nettoændring i likviditet | -2,07 mio. | -85,97 % |
Fri pengestrøm | -1,27 mio. | -22,46 % |
Om
Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA developing proprietary therapeutics primarily for the treatment of central nervous system disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds. In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni - a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group.
Titan's principal asset is Probuphine, a slow-release implant formulation of buprenorphine for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016. It was licensed to Braeburn Pharmaceuticals for marketing and commercialization. Wikipedia
Grundlagt
1991
Hovedkvarter
Website
Ansatte
4
